NEW YORK, April 12 (GenomeWeb News) - Oxford Genome Sciences and researchers at the Department of Clinical Pharmacology of the University of Oxford are collaborating to discover clinical biomarkers for colorectal cancer, OGeS said today.
In forming the collaboration, OGeS joins an ongoing research consortium between the University of Oxford and GE Healthcare to develop personalized diagnostic tests and treatments for colorectal cancer. The consortium was founded last fall with funding from GE Healthcare.
Under the two-year agreement, OGeS will use its proteomics technology and Oxford Genome Anatomy Project protein database to discover diagnostics for early- and late-stage colorectal cancer, and to identify protein biomarkers of recurring colorectal cancer. OGeS will analyze protein profiles of blood samples, as well as genetic variations and risk factors, from colorectal cancer patients.
Last week, OGeS and Biosite said they were also collaborating to develop new diagnostics for relapsing colorectal cancer.